title: A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
abstract: MicroRNAs (miRNA, miR) have been implicated as promising blood-based biomarkers for schizophrenia patients. This study aimed to clinically validate miRNA as potential schizophrenia biomarkers. Plasma levels of 10 miRNAs were analyzed using qPCR in a cohort of 61 schizophrenia patients and 62 normal controls, as well as 25 patients particularly selected for a six-week antipsychotic treatment course. Positive And Negative Syndrome Scale (PANSS), Global Assessment Scale (GAS) and Clinical Global Impression (CGI) were administered to assess the clinical symptoms. The results demonstrated that a panel of miRNAs consisting of miR-30e, miR-181b, miR-34a, miR-346 and miR-7 had significantly increased expression levels with significant combined diagnostic value (AUC:0.713; sensitivity:35.5%; specificity:90.2%). In response to pharmacological treatment, expression levels of miR-132, miR-181b, miR-432 and miR-30e were significantly decreased. In addition, the improvement of clinical symptomatology was significantly correlated with the changes of miR-132, miR-181b, miR-212 and miR-30e expression levels. Furthermore, the decreases of plasma levels of miR-132 and miR-432 were significantly greater in high-effect subgroup than those in low-effect subgroup after six-week treatment course. We conclude that miR-30e, miR-181b, miR-34a, miR-346 and miR-7 combined as a panel are potentially useful non-invasive biomarkers for schizophrenia diagnosis. Markers miR-132, miR-181b, miR-30e and miR-432 are potential indicators for symptomatology improvements, treatment responses and prognosis for schizophrenia patients.
authors: Prevention and Treatment Center for Psychological Diseases, No.102 Hospital of Chinese People's Liberation Army, Changzhou, Jiangsu, P.R. China; Department of Psychology and Psychiatry, Second Military Medical University, Shanghai, P.R. China.
authors: Xin-yang
authors: XY
authors: Sun
authors: Jin
authors: J
authors: Zhang
authors: Wei
authors: W
authors: Niu
authors: Wei
authors: W
authors: Guo
authors: Hong-tao
authors: HT
authors: Song
authors: Heng-yu
authors: HY
authors: Li
authors: Hui-min
authors: HM
authors: Fan
authors: Lin
authors: L
authors: Zhao
authors: Ai-fang
authors: AF
authors: Zhong
authors: Yun-hua
authors: YH
authors: Dai
authors: Zhong-min
authors: ZM
authors: Guo
authors: Li-yi
authors: LY
authors: Zhang
authors: Jim
authors: J
authors: Lu
authors: Qiao-li
authors: QL
authors: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000097:blood / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D060888:Real-Time Polymerase Chain Reaction; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D014408:Biomarkers, Tumor; D035683:MicroRNAs
keywords: CGI; GAS; PANSS; antipsychotics; biomarker; microRNA; qPCR; schizophrenia